Jazz Pharmaceuticals Q3 Adj. EPS $(3.88) Misses $(3.86) Estimate, Sales $1.243B Beat $1.208B Estimate
Benzinga Newsdesk 10 hours ago
NewsEarningsEarnings BeatsEarnings Misses
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly losses of $(3.88) per share which missed the analyst consensus estimate of $(3.86) by 0.52 percent. This is a 147.72 percent decrease over earnings of $8.13 per
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly losses of $(3.88) per share which missed the analyst consensus estimate of $(3.86) by 0.52 percent. This is a 147.72 percent decrease over earnings of $8.13 per share from the same period last year. The company reported quarterly sales of $1.243 billion which beat the analyst consensus estimate of $1.208 billion by 2.94 percent. This is a 10.39 percent increase over sales of $1.126 billion the same period last year.